Hyperbaric Oxygen Therapy for Treating PTSD and Cognitive Decline with Dr. Mohammed Elamir Aviv Clinics TRANSCRIPT
Release Date: 09/26/2024
Transforming MRI Data to Identify Biomarkers for Diagnosing and Treating Back Pain with Brent Ness Aclarion TRANSCRIPT
Empowered Patient Podcast
Brent Ness, CEO and President of Aclarion, highlights the challenges of diagnosing and treating chronic lower back pain, a leading driver of healthcare costs and opioid addiction. Traditional MRI and CT imaging do not reveal the biochemical source of pain within spinal discs, leading to misdiagnosis and unsuccessful treatment. The Aclarion technology uses MR spectroscopy to measure pain-causing biomarkers and, through a cloud-based, AI-powered SaaS model, analyzes the raw data and sends the physician a report within minutes. Brent explains, "The diagnosis and accurate treatment planning...
info_outline
Transforming MRI Data to Identify Biomarkers for Diagnosing and Treating Back Pain with Brent Ness Aclarion
Empowered Patient Podcast
Brent Ness, CEO and President of Aclarion, highlights the challenges of diagnosing and treating chronic lower back pain, a leading driver of healthcare costs and opioid addiction. Traditional MRI and CT imaging do not reveal the biochemical source of pain within spinal discs, leading to misdiagnosis and unsuccessful treatment. The Aclarion technology uses MR spectroscopy to measure pain-causing biomarkers and, through a cloud-based, AI-powered SaaS model, analyzes the raw data and sends the physician a report within minutes. Brent explains, "The diagnosis and accurate treatment planning...
info_outline
First Non-Steroidal MRA Drug Approved for Heart Failure with Dr. Alanna Morris-Simon Bayer TRANSCRIPT
Empowered Patient Podcast
Dr. Alanna Morris-Simon, Senior Medical Director for US Medical Affairs at Bayer, describes the symptoms and diagnostics used to classify heart failure and the key at-risk populations for this condition. The rapidly evolving landscape of heart failure treatments now includes the Bayer drug KERENDIA, a non-steroidal MRA approved to reduce cardiovascular death and heart failure in adults with an ejection fraction of 40% or more. This drug is part of an emerging trend to treat multiple related conditions simultaneously and could prevent the onset of heart failure and treat established...
info_outline
First Non-Steroidal MRA Drug Approved for Heart Failure with Dr. Alanna Morris-Simon Bayer
Empowered Patient Podcast
Dr. Alanna Morris-Simon, Senior Medical Director for US Medical Affairs at Bayer, describes the symptoms and diagnostics used to classify heart failure and the key at-risk populations for this condition. The rapidly evolving landscape of heart failure treatments now includes the Bayer drug KERENDIA, a non-steroidal MRA approved to reduce cardiovascular death and heart failure in adults with an ejection fraction of 40% or more. This drug is part of an emerging trend to treat multiple related conditions simultaneously and could prevent the onset of heart failure and treat established...
info_outline
AI-Powered Virtual Tumor Boards Democratize Access to Expert Cancer Analysis with Steve Brown and Lisa Booth CureWise TRANSCRIPT
Empowered Patient Podcast
Steve Brown, Founder and CEO and Lisa Booth, Vice President of Operations of CureWise, are both cancer survivors, which led them to develop an AI-powered tumor board platform to advance cancer diagnoses and treatment. This approach to precision medicine provides patients with the opportunity to better understand their specific condition, educating them about possible courses of action that may be more appropriate than the standard of care. The platform also helps patients find relevant clinical trials and manage the side effects of their treatments. Steve explains, "So the mission...
info_outline
AI-Powered Virtual Tumor Boards Democratize Access to Expert Cancer Analysis with Steve Brown and Lisa Booth CureWise
Empowered Patient Podcast
Steve Brown, Founder and CEO and Lisa Booth, Vice President of Operations of CureWise, are both cancer survivors, which led them to develop an AI-powered tumor board platform to advance cancer diagnoses and treatment. This approach to precision medicine provides patients with the opportunity to better understand their specific condition, educating them about possible courses of action that may be more appropriate than the standard of care. The platform also helps patients find relevant clinical trials and manage the side effects of their treatments. Steve explains, "So the mission...
info_outline
Effectively Treating Rare Epileptic Disorder Dravet Syndrome with Nayla Chaijale UCB TRANSCRIPT
Empowered Patient Podcast
Nayla Chaijale, Medical Strategy Lead for Rare Syndromes at UCB, describes Dravet syndrome, a rare, medication-resistant epileptic encephalopathy that involves seizures and significant co-morbidities like cognitive and developmental delays. Their approved drug FINTEPLA has a unique mechanism of action that modulates pathways in the brain and has demonstrated a significant reduction in the frequency of convulsive seizures in those with this condition. Nayla notes that the good news is that most patients with Dravet syndrome have a mutation in the SCN1A gene, a critical biomarker that...
info_outline
Effectively Treating Rare Epileptic Disorder Dravet Syndrome with Nayla Chaijale UCB
Empowered Patient Podcast
Nayla Chaijale, Medical Strategy Lead for Rare Syndromes at UCB, describes Dravet syndrome, a rare, medication-resistant epileptic encephalopathy that involves seizures and significant co-morbidities like cognitive and developmental delays. Their approved drug FINTEPLA has a unique mechanism of action that modulates pathways in the brain and has demonstrated a significant reduction in the frequency of convulsive seizures in those with this condition. Nayla notes that the good news is that most patients with Dravet syndrome have a mutation in the SCN1A gene, a critical biomarker that...
info_outline
AI Platform Facilitating Improved Accessibility to Clinical Trials with Vanessa Lemarié myTomorrows TRANSCRIPT
Empowered Patient Podcast
Vanessa Lemarié, Chief Operations Officer at myTomorrows, which is a platform for connecting patients, physicians, and clinical trial sponsors using a Trial Search AI tool designed to improve the accuracy of matching patients with suitable trials. The technology aims to speed up trial recruitment, increase diversity by reaching underserved populations, and ultimately shorten the drug development timeline. There is a particular focus on patients with no treatment options or who have not responded to current therapies. Vanessa explains, "We are all about patients. First and foremost, we want...
info_outline
AI Platform Facilitating Improved Accessibility to Clinical Trials with Vanessa Lemarié myTomorrows
Empowered Patient Podcast
Vanessa Lemarié, Chief Operations Officer at myTomorrows, which is a platform for connecting patients, physicians, and clinical trial sponsors using a Trial Search AI tool designed to improve the accuracy of matching patients with suitable trials. The technology aims to speed up trial recruitment, increase diversity by reaching underserved populations, and ultimately shorten the drug development timeline. There is a particular focus on patients with no treatment options or who have not responded to current therapies. Vanessa explains, "We are all about patients. First and foremost, we want...
info_outlineDr. Mohammed Elamir, lead physician at Aviv Clinics, offers diagnostics and treatments for brain injuries such as PTSD, stroke, and traumatic brain injury and to address cognitive decline. After comprehensive physical and mental assessment, including brain scans, patients receive hyperbaric oxygen therapy and other therapies like psychotherapy and neurocognitive training. Individualized plans are designed to get to the root causes of neurological and cognitive issues and stimulate the growth of new cells and blood flow, even for patients with long-standing conditions.
Dr. Mo explains, "Our pre-assessment testing is a lot more rigorous than your kind of annual physical. We do three to five days of testing that can involve medical evaluations with the medical doctors and advanced blood work for different biomarkers for injury or inflammation. Two very specific brain scans that I think separate our assessment from most, and one is an MRI with DTI analysis. That is a microstructure analysis of the brain. So we can look at the nerve tracks running through the brain, how well-connected, and how dense they are."
"If somebody’s approved for the treatment, they would undergo up to a 12-week treatment regimen involving hyperbaric oxygen therapy. And we can go into the details of that oxygen therapy, but in addition to that, they’ll have other appointments, whether it’s PT, psychological counseling, or neurocognitive training. And by the end of the 12 weeks, they should be feeling better, but objectively, we want to see why. We repeat the entire pre-treatment assessment at the end so we can have an objective comparison."
#AvivClinics #HBOT #Hyperbaricmedicine #PTSD #Stoke #Aging
